|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:accessories
|
gptkb:various_countries
|
|
gptkbp:average_temperature
|
2 to 8 degrees Celsius
|
|
gptkbp:brand
|
Vidprevtyn
|
|
gptkbp:clinical_trial
|
over 35,000
multiple countries
Phase 3
published in medical journals
|
|
gptkbp:collaborator
|
gptkb:GSK
|
|
gptkbp:community_health
|
gptkb:significant
|
|
gptkbp:developer
|
gptkb:Sanofi
|
|
gptkbp:dosage_form
|
recommended after initial series
two doses
|
|
gptkbp:first_dose_interval
|
21 days
|
|
gptkbp:funding
|
government and private sector
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sanofi's COVID-19 vaccine
|
|
gptkbp:is_a_platform_for
|
recombinant DNA technology
|
|
gptkbp:is_effective_against
|
approximately 70%
|
|
gptkbp:is_vulnerable_to
|
gptkb:healthcare_professionals
gptkb:liquid
global
increased during pandemic
monitored continuously
against variants
subunit vaccine
against severe disease
reducing hospitalizations
standard refrigeration
nationwide campaigns
ongoing for improved formulations
CDC and WHO guidelines
protein subunit
|
|
gptkbp:manufacturing_sites
|
multiple locations
|
|
gptkbp:market_position
|
gptkb:2021
|
|
gptkbp:partnership
|
gptkb:GSK
|
|
gptkbp:regulatory_compliance
|
gptkb:European_Medicines_Agency
gptkb:U._S._Food_and_Drug_Administration
|
|
gptkbp:route_of_administration
|
intramuscular
|
|
gptkbp:safety_features
|
well-studied
|
|
gptkbp:second_dose_interval
|
21 days
|
|
gptkbp:side_effect
|
mild to moderate reactions
|
|
gptkbp:target_audience
|
adults
|
|
gptkbp:targets
|
gptkb:COVID-19
|
|
gptkbp:type
|
recombinant protein vaccine
|
|
gptkbp:vaccine_data
|
shared with health authorities.
|
|
gptkbp:vaccine_trials
|
ongoing for new variants
expanded to children
|
|
gptkbp:who_prequalification
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Lonza_Group
|
|
gptkbp:bfsLayer
|
6
|